Verrica Pharmaceuticals (VRCA) is trading down at $4.31 (-1.60%), as of the latest quote. It operates in the Health Care sector.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | — | — | $12.0M | $9.03M | $5.12M | $7.57M | $35.6M |
| Growth (year over year) | — | — | — | — | — | −24.7% | −43.3% | +47.7% | +370.2% |
| Gross profit | — | — | — | — | — | — | $4.62M | $4.97M | — |
| Gross margin | — | — | — | — | — | — | 90.2% | 65.6% | — |
| Operating income | −$4.46M | −$21.9M | −$30.1M | −$40.2M | −$30.9M | −$21.3M | −$65.8M | −$65.9M | −$12.2M |
| Operating margin | — | — | — | — | −257.6% | −235.8% | −1283.4% | −871.3% | −34.2% |
| Net income | −$4.46M | −$20.6M | −$28.2M | −$42.7M | −$35.1M | −$24.5M | −$67.0M | −$76.6M | −$17.9M |
| Net margin | — | — | — | — | −292.3% | −271.1% | −1307.5% | −1012.1% | −50.3% |
| EPS (diluted) | −$156.00 | −$141.00 | −$113.00 | −$171.00 | −$13.00 | −$7.20 | −$14.80 | −$14.78 | −$1.68 |
| Balance sheet | |||||||||
| Cash and equivalents | $8.66M | $10.3M | $9.24M | $10.7M | $15.8M | $34.3M | $69.5M | $46.3M | $30.1M |
| Total assets | $9.08M | $91.9M | $68.4M | $74.2M | $80.1M | $44.7M | $81.6M | $54.1M | $47.1M |
| Total liabilities | $616.0K | $2.48M | $3.41M | $41.2M | $47.5M | $4.69M | $61.8M | $64.0M | $22.4M |
| Long-term debt | — | — | — | — | — | $0 | $42.9M | $31.0M | $0 |
| Shareholders' equity | −$7.04M | $89.4M | $65.0M | $33.0M | $32.6M | $40.0M | $19.8M | −$9.86M | $24.7M |
| Cash flow | |||||||||
| Operating cash flow | −$4.58M | −$17.9M | −$27.4M | −$30.2M | −$27.6M | −$18.6M | −$38.6M | −$60.9M | −$17.6M |
| Capital expenditure | — | $774.0K | $682.0K | $1.47M | $883.0K | $302.0K | $362.0K | $27.0K | $0 |
| Free cash flow | — | −$18.6M | −$28.1M | −$31.7M | −$28.5M | −$19.0M | −$38.9M | −$61.0M | −$17.6M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | −$1.78M | — | $3.44M | $12.7M | $14.3M | $5.09M | $5.02M | $5.86M |
| Growth (year over year) | −161.1% | — | −10.1% | +145.4% | — | — | +46.1% | −53.8% |
| Gross profit | −$2.18M | — | $2.74M | — | — | — | — | — |
| Gross margin | — | — | 79.6% | — | — | — | — | — |
| Operating income | −$20.7M | — | −$8.13M | $1.51M | $1.63M | −$7.19M | −$9.71M | −$13.1M |
| Operating margin | — | — | −236.4% | 11.9% | 11.3% | −141.2% | −193.4% | −223.4% |
| Net income | −$22.9M | — | −$9.74M | $204.0K | −$274.0K | −$8.07M | −$9.68M | −$13.2M |
| Net margin | — | — | −283.3% | 1.6% | −1.9% | −158.6% | −192.8% | −224.4% |
| EPS (diluted) | −$4.88 | — | −$1.03 | $0.02 | −$0.03 | −$0.64 | −$0.45 | −$0.62 |
| Balance sheet | ||||||||
| Cash and equivalents | $23.0M | $46.3M | $29.6M | $15.4M | $21.1M | $30.1M | $20.6M | $11.2M |
| Total assets | $32.9M | $54.1M | $42.2M | $39.1M | $40.9M | $47.1M | $38.8M | $36.0M |
| Total liabilities | $67.0M | $64.0M | $60.8M | $56.6M | $57.9M | $22.4M | $22.7M | $31.7M |
| Long-term debt | $43.3M | $31.0M | $27.8M | $24.6M | $21.6M | $0 | — | — |
| Shareholders' equity | −$34.1M | −$9.86M | −$18.6M | −$17.5M | −$17.0M | $24.7M | $16.1M | $4.31M |
| Cash flow | ||||||||
| Operating cash flow | −$8.56M | — | −$12.7M | −$10.0M | $9.69M | −$4.59M | −$9.16M | −$9.28M |
| Capital expenditure | $16.0K | — | — | — | $0 | $0 | — | — |
| Free cash flow | −$8.57M | — | — | — | $9.69M | −$4.59M | — | — |
From Verrica Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Verrica Pharmaceuticals in our feed yet.